Investors & Media

Stock Info

NASDAQBCLI

Recent News

Mar 27, 2023

BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration...

Mar 21, 2023

BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...

Jan 10, 2023

BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study

Serum and cerebrospinal fluid samples from the Phase 3 study of NurOwn® in ALS to be donated to the NEALS biorepository for use by the research community NEW YORK, Jan. 10, 2023 /PRNewswire/ --...

View All

Events

Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Update Call

Thursday, March 30, 2023

8:00am - 9:00am EDT

Participant Numbers:
Toll Free: 877 545 0523
International: 973 528 0016
Entry Code: 943129

Replay Numbers:
Toll Free: 877 481 4010
International: 919 882 2331
Replay Passcode: 47908

Email Alerts